Literature DB >> 16881863

c-Jun N-terminal kinase negatively regulates dsRNA and RSV induction of tumor necrosis factor- alpha transcription in human epithelial cells.

Michael J Stewart1, Sandhya B Kulkarni, Tiffany R Meusel, Farhad Imani.   

Abstract

Secretion of inflammatory cytokines is the initial step of the immune response to viral infections. This innate immune response is mediated by the expression of a variety of cytokines, exemplified by tumor necrosis factor- alpha (TNF-alpha). The presence of dsRNA during viral infections is a key step in activation of several signaling pathways, including protein kinase R (PKR), toll-like receptor 3 (TLR3), mitogen-activated protein kinase (MAPK), activator protein-1 (AP-1), interferon regulatory factors (IRFs), and NF-kappaB pathways, which are all relevant in the expression of inflammatory cytokines. We previously reported that PKR and p38 MAPK were required for dsRNA and viral induction of inflammatory cytokines in epithelial cells. Here, we report that activation of c-Jun N-terminal kinase (JNK) during dsRNA treatment or respiratory syncytial viral (RSV) infection negatively regulates the induction of TNF-alpha in human epithelial cells. Inhibition of JNK by a pharmacologic inhibitor showed that expression of TNF-alpha increased following both dsRNA treatment and infection with RSV. Importantly, transfection of epithelial cells with a dominant-negative mutant of JNK significantly increased dsRNA induction of TNF-alpha. The mechanism by which JNK inhibition increases TNF-alpha induction appears to be through p38 MAPK activation. Our data show that JNK is a negative regulator of dsRNA and RSV induction of TNF-alpha expression and, thus, may act as a counterbalance to proinflammatory signals generated during viral infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16881863     DOI: 10.1089/jir.2006.26.521

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  8 in total

1.  TAK1 regulates NF-ΚB and AP-1 activation in airway epithelial cells following RSV infection.

Authors:  Nilay Dey; Tianshuang Liu; Roberto P Garofalo; Antonella Casola
Journal:  Virology       Date:  2011-08-10       Impact factor: 3.616

2.  Protein kinase R is a novel mediator of CD40 signaling and plays a critical role in modulating immunoglobulin expression during respiratory syncytial virus infection.

Authors:  Sheetal A Thakur; Zachary B Zalinger; Teresa R Johnson; Farhad Imani
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

3.  Inositol-requiring enzyme 1 inhibits respiratory syncytial virus replication.

Authors:  Ihab Hassan; Kayla S Gaines; Wesley J Hottel; Ryan M Wishy; Sara E Miller; Linda S Powers; D Thomas Rutkowski; Martha M Monick
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

4.  RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response.

Authors:  Fang Guo; Jennifer Mead; Nishat Aliya; Lijuan Wang; Andrea Cuconati; Lai Wei; Kui Li; Timothy M Block; Ju-Tao Guo; Jinhong Chang
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

5.  A Cross-Study Biomarker Signature of Human Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus.

Authors:  Luiz Gustavo Gardinassi
Journal:  Adv Virol       Date:  2016-05-04

Review 6.  Receptors for Respiratory Syncytial Virus Infection and Host Factors Regulating the Life Cycle of Respiratory Syncytial Virus.

Authors:  Ziheng Feng; Lili Xu; Zhengde Xie
Journal:  Front Cell Infect Microbiol       Date:  2022-02-25       Impact factor: 5.293

7.  Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB.

Authors:  Natalie J Thornburg; Sarah L Hayward; James E Crowe
Journal:  mBio       Date:  2012-12-18       Impact factor: 7.867

8.  RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages.

Authors:  Fuan Wang; Xiujuan Gao; John W Barrett; Qing Shao; Eric Bartee; Mohamed R Mohamed; Masmudur Rahman; Steve Werden; Timothy Irvine; Jingxin Cao; Gregory A Dekaban; Grant McFadden
Journal:  PLoS Pathog       Date:  2008-07-11       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.